Molecular Neurodegeneration
Alzheimer’s vaccine prompts an immune response in 12 adults
All 12 vaccine recipients developed antibodies after two doses, while four placebo recipients showed no measurable response in a randomized phase 1 trial.All 12 vaccine recipients developed antibodies after two doses, while four placebo recipients showed no measurable response in a randomized phase 1 trial.
Randomized trial · 16 peopleAlzheimer's disease
Who was studied16 healthy adults aged 40–60 years, through week 22, against placebo recipients
What changedAll vaccinated adults (12/12) developed anti-amyloid antibodies after two immunizations, while placebo recipients had no measurable response
The catchAssay plates can alter amyloid structure; a second assay was used to reduce artifacts